Oligonucleotides Industry Trends: Market to Reach USD 15.8 Billion by 2036 at 11.8% CAGR

The global oligonucleotides market was valued at USD 4.6 billion in 2025 and is projected to reach USD 15.8 billion by 2036, expanding at a CAGR of 11.8% from 2026 to 2036. The market growth is driven by increasing applications of oligonucleotides in therapeutics, diagnostics, drug discovery, precision medicine, and genetic research, along with rising investments in nucleic acid-based therapies.

👉 Get sample market research report copy today@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86409

Market Overview

The oligonucleotides market is becoming an important part of biotechnology and the pharmaceutical industry, mostly because nucleic acid based therapies and diagnostic technologies are used more and more these days.
Oligonucleotides are short sequences, made of DNA or RNA, and they are mainly used in genetic research, in molecular diagnostics, plus in treating diseases like cancer neurological disorders and rare genetic conditions. Basically these molecules help aim at specific genes for personalized medicine and precision therapy style approaches, even when the overall process feels complex.

The market has seen a lot of growth as investments keep moving into RNA therapeutics and as gene based treatment technologies keep improving. The good results from RNA drugs and vaccines also make people more interested in oligonucleotide studies and the manufacturing side of it. Higher demand for early disease diagnosis, more ongoing biotechnology research work and wider use in drug discovery are all pushing market expansion worldwide.

Analysts' Viewpoint

The oligonucleotides market, is getting a lot of attention, mostly because RNA based therapeutics are growing fast and precision medicine seems to be everywhere now. The market can really take off in the future, mainly because more people are dealing with cancer, rare genetic disorders and other long lasting illnesses. Pharma and biotech firms are investing more into research programs to create more precise and actually better treatments and this is likely to open up meaningful growth chances for the market in the next few years.

There's also this other side of it, the progress in oligonucleotide synthesis methods, along with delivery systems. Businesses are trying to make oligonucleotide medicines more stable, more effective and safer, so their use is stretching beyond treatment and into diagnostics too. On top of that, the rising number of regulatory nods for RNA drugs has boosted confidence across investors and healthcare organizations.

High manufacturing costs, really complex regulatory requirements and problems related to scaling up production on a large scale, could curb growth a bit. Even with that though, the bigger picture still looks positive. The reason is that demand for personalized medicine, plus gene targeted treatments, is keep on rising around the globe. North America will stay on top because of solid biotechnology infrastructure and strong research funding, while Asia Pacific is expected to grow rapidly due to more healthcare investments and wider pharmaceutical manufacturing.

Analysis of Key Players

The competitive landscape is characterized by technological innovation, manufacturing capacity expansion, strategic partnerships, customized synthesis capabilities, and investments in nucleic acid therapeutics.

Leading companies operating in the global oligonucleotides market include:

• Thermo Fisher Scientific Inc.

• Danaher Corporation
• Merck KGaA
• Eurofins Scientific
• Integrated DNA Technologies, Inc.
• Agilent Technologies, Inc.
• LGC Biosearch Technologies
• WuXi AppTec
• Nitto Denko Corporation
• Sarepta Therapeutics, Inc.
• Ionis Pharmaceuticals, Inc.
• Other Prominent Players

Strategic investments in large-scale oligonucleotide manufacturing, therapeutic development, custom synthesis, delivery technologies, and research partnerships remain key competitive strategies among market participants.

Recent Developments (2025-2026)

• In May 2026, Ionis Pharmaceuticals, Inc. has announced its partner, Biogen, shared compelling topline results from the Phase 2 CELIA study looking at diranersen (IONIS-MAPTRx/BIIB080), an investigational antisense oligonucleotide (ASO) treatment aiming at tau, in people with early Alzheimer's disease (AD). The CELIA findings offer the first real evidence, from a randomized Phase 2 study of a tau-directed therapy, showing both strong biomarker impact and cognitive benefit in early AD.

• In December 2025, Luxna Biotech Co., Ltd. and one of the largest contract development and manufacturing organizations (CDMO) focusing on oligonucleotide therapeutics, BioSpring GmbH have announced a new kind of collaboration. In this new project, Luxna will push forward an oligonucleotide therapeutic for an undisclosed target, while BioSpring provides its know-how across process development, analytical characterization and clinical manufacturing for oligonucleotides.

• In April 2024, Asahi Kasei Bioprocess (AKB), part of the Asahi Kasei Group, and Axolabs, has announced a sort of strategic partnership in this rapidly growing area of oligonucleotide therapeutics. The teams will work together to create a cutting edge oligonucleotide cGMP production plant, across 59,000 square feet (about 5,481 square meters) in Berlin.

👉 Discuss Implications for Your Industry Request Sample Market Research Report PDF@ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=86409

Key Developments & Trends

• RNA-based Therapeutics: Growing development of antisense and RNA interference therapies is creating significant demand for oligonucleotides.

• Precision Medicine: Oligonucleotides enable targeted modulation of disease-associated genes and molecular pathways.

• Advanced Synthesis: Improvements in automated synthesis and purification are increasing production efficiency and scalability.

• Gene Regulation: Increasing research into gene expression and silencing is expanding oligonucleotide applications.

• Custom Oligonucleotides: Rising demand from pharmaceutical, biotechnology, academic, and diagnostic laboratories is supporting custom synthesis services.

Challenges

• High Manufacturing Costs: Complex synthesis and purification processes can increase production costs.

• Delivery Challenges: Efficiently delivering oligonucleotides to specific tissues and cells remains technically challenging.

• Regulatory Complexity: Oligonucleotide therapeutics require extensive characterization, quality control, and regulatory evaluation.

• Manufacturing Scalability: Scaling production while maintaining purity and consistency can be challenging for advanced therapeutic applications.
Opportunities

• RNA Therapeutics: Expansion of RNA-based drug development offers substantial growth opportunities.

• Rare Disease Treatments: Oligonucleotides can enable targeted therapeutic approaches for specific genetic disorders.

• Personalized Medicine: Customized molecular therapies can support individualized treatment strategies.

• Contract Manufacturing: Growing outsourcing of oligonucleotide synthesis and development creates opportunities for CDMOs and specialized manufacturers.
Market Segmentation

Product Type

• DNA Oligonucleotides
• RNA Oligonucleotides
• Modified Oligonucleotides

Therapeutic Type

• Antisense Oligonucleotides (ASOs)
• Small Interfering RNA (siRNA)
• MicroRNA (miRNA)
• Aptamers
• CpG Oligonucleotides
• Others

Synthesis Method

• Solid-Phase Synthesis
• Liquid-Phase Synthesis
• Enzymatic Synthesis

Application

• Therapeutics
• Diagnostics
• Research & Development

End-user

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations (CROs) & CDMOs
• Diagnostic Laboratories

Conclusion

The global oligonucleotides market is expected to witness robust growth through 2036, driven by increasing adoption of nucleic acid-based therapeutics, expanding applications in precision medicine and molecular diagnostics, and rising investments in genetic research. Advancements in oligonucleotide synthesis, chemical modification, delivery technologies, and scalable manufacturing will further support market development. As pharmaceutical and biotechnology companies continue to develop targeted RNA and gene-regulating therapies, oligonucleotides are expected to play an increasingly important role in the future of precision healthcare.

👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=86409

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com

This release was published on openPR.